Farmakokinetika

**Farmakokinetika**, skraćeno *PK*, (od starogrčkog *pharmakon* "lek" i *kinetikos* "vezano za kretanje") je grana farmakologije koja se bavi izučavanjem promena supstanci doziranih u žive organizme. Supstance od interesa su farmaceutski agensi, hormoni, nutrijenti, i toksini. Ona pokužava da otkrije sudbinu leka od momenta njegovog unosa do tačke u kojoj je kompletno eliminisan iz tela.

Farmakokinetika opisuje kako telo deluje na specifični lek nakon doziranja putem mehanizama apsorpcije i distribucije, kao i hemijske promene supstane u telu (e.g. posredstvom metaboličkih enzima kao što su enzimi citohrom P450 ili glukuronoziltransferaza), i efekte i puteve izlučivanja metabolita leka. Farmakokinetička svojstva leka mogu da budu uslovljena faktorima poput mesta administriranja i doze leka. Ti faktori mogu da utiču na brzinu apsorpcije. Farmakokinetika se često studira zajedno sa farmakodinamikom.

## Reference

## Literatura

* 
* 
* Alberts et al., *Introducción a la Biología Celular*, pág. 375-376, 2ª edición, Ed. Médica Panamericana
* Alberts et al., *Biología Molecular de la célula*, pág. 595, 4ª edición, Ed. Omega
* Armijo JA. 2003. *Farmacocinética: Absorción, Distribución y Eliminación de los Fármacos*. En: Flórez J, Armijo JA, Mediavilla A, *Farmacología Humana*, 4ta edición. Masson. Barcelona. pp: 51-79.
* Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW., *Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection*, Curr Top Med Chem. 2005;5(11):1033-8.
* Beal, S.; Sheiner L.B. "The NONMEM System". The American Statistician 34: 118–9. (1980). doi:10.2307/2684123.
* Cooper, *La célula*, pág 470-471, 2ª edición, Ed. Marbán
* Covey TR, Lee ED, Henion JD "High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samples". Anal. Chem. 58: 2453–60. (October 1986). doi:10.1021/ac00125a022. .
* Covey TR, JB Crowther, EA Dewey, JD Henion "Thermospray liquid chromatography/mass spectrometry determination of drugs and their metabolites in biological fluids". Anal. Chem. 57 (2): 474–81. (February 1985). doi:10.1021/ac50001a036. .
* Danielson P (2002). "The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans". Curr Drug Metab 3 (6): 561-97. .
* Davies K (1995). "Oxidative stress: the paradox of aerobic life". Biochem Soc Symp 61: 1-31. .
* Devlin, T. M. 2004. *Bioquímica*, 4ª edición. Reverté, Barcelona. 
* Galvão T, Mohn W, de Lorenzo V (2005). "Exploring the microbial biodegradation and biotransformation gene pool". Trends Biotechnol 23 (10): 497-506. .
* Hsieh Y, Korfmacher WA "Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening". Current Drug Metabolism 7 (5): 479–89.(June 2006). . Disponible en http://www.bentham-direct.org/pages/content.php?CDM/2006/00000007/00000005/0004F.SGM.
* Janssen D, Dinkla I, Poelarends G, Terpstra P (2005). "Bacterial degradation of xenobiotic compounds: evolution and distribution of novel enzyme activities". Environ Microbiol 7 (12): 1868-82. .
* Kathleen Knights; Bronwen Bryant (2002). *Pharmacology for Health Professionals*. Amsterdam: Elsevier. .
* King C, Rios G, Green M, Tephly T (2000). "UDP-glucuronosyltransferases". Curr Drug Metab 1 (2): 143-61. .
* Malcolm Rowland, Thomas N. Tozer. "Farmacocinética clínica: Conceptos y Aplicaciones"
* Pharmacokinetics. (2006). En *Mosby's Dictionary of Medicine, Nursing, & Health Professions*. Philadelphia, PA: Elsevier Health Sciences. Disponible en http://www.credoreference.com/entry/6686418 Última visita 11, diciembre de 2008,
* Sheehan D, Meade G, Foley V, Dowd C (2001). "Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily". Biochem J 360 (Pt 1): 1-16. .
* Sheiner, L.B.; Beal, S.L., Rosenberg, B. Marathe, V.V. "Forecasting Individual Pharmacokinetics". Clin. Pharmacol. Ther. 26: 294–305. (1979). .
* Sheiner, L.B.; Rosenberg, B., Marathe, V.V. "Estimation of Population Characteristics of Pharmacokinetic Parameters from Routine Clinical Data". J. Pharmacokin. Biopharm. 5: 445–79. 1.997 doi:10.1007/BF01061728.
* Sies H (1997). "Oxidative stress: oxidants and antioxidants". Exp Physiol 82 (2): 291-5. .
* Singh SS., *Preclinical pharmacokinetics: an approach towards safer and efficacious drugs*, Curr Drug Metab. 2006 Feb;7(2):165-82.
* Testa B, Krämer S (2006). "The biochemistry of drug metabolism--an introduction: part 1. Principles and overview". Chem Biodivers 3 (10): 1053-101. .
* Tetko IV, Bruneau P, Mewes HW, Rohrer DC, Poda GI., *Can we estimate the accuracy of ADME-Tox predictions?,* Drug Discov Today. 2006 Aug;11(15-16):700-7, pre-print .
* Tu B, Weissman J (2004). "Oxidative protein folding in eukaryotes: mechanisms and consequences". J Cell Biol 164 (3): 341-6. .
* Vertuani S, Angusti A, Manfredini S (2004). "The antioxidants and pro-antioxidants network: an overview". Curr Pharm Des 10 (14): 1677-94. .

## Povezano
* Bioraspoloživost
* Enzimska kinetika
* Farmakodinamika

## Vanjske veze
* http://vam.anest.ufl.edu/demos/onecompbolus.html 
* http://www.biokinetica.pl/en.html
* http://cti.itc.virginia.edu/~cmg/Demo/scriptFrame.html